

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Presently Amended) A method for ~~detecting~~ determining the binding of a test substance to an $\alpha 2\delta$ subunit of a calcium channel comprising the steps of :
 - (a) contacting a sample of neuroblastoma cell ~~membrane~~ membranes ~~sample~~ comprising the $\alpha 2\delta$ subunit of a calcium channel with gabapentin and a test substance;
 - (b) detecting binding of the gabapentin to the cell ~~membrane~~ membranes; and
 - (c) comparing the ~~level~~ amount of binding of gabapentin of the sample as compared with a control sample lacking the test substance, thereby determining the binding of the test substance to the $\alpha 2\delta$ subunit.
2. (Original) The method of claim 1 wherein the cell membranes are part of intact cells.
3. (Original) The method of claim 1 wherein the cell membranes are obtained from an isolated cell membrane preparation.
4. (Original) The method of claim 1 wherein the neuroblastoma cell membranes are IMR32, SK-N-MC or NG 108 cell membranes.
5. (Original) The method of claim 1 wherein the neuroblastoma cell membranes are differentiated neuroblastoma cell membranes.
6. (Original) The method of claim 5 wherein the differentiated cell membranes are obtained following incubation with BrdU.

7. (Original) The method of claim 1 further comprising the step of separating the cell membranes from unbound gabapentin.
8. (Original) The method of claim 1 wherein the comparing step comprises measuring binding of labeled gabapentin bound to the cell membranes.
9. (Original) A compound identified using the method of claim 1.
10. (Original) A test substance identified by a method comprising the steps of:
 - (a) contacting a neuroblastoma cell membrane sample comprising $\alpha 2\delta$ subunit of a calcium channel with gabapentin and a test substance;
 - (b) detecting binding of the gabapentin to the cell membrane; and
 - (c) comparing the level of binding of gabapentin as compared with a control sample lacking the test substance.
11. (Canceled).